• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAA 5.56% 17.0¢

PHARMAUST LIMITED - Announcements

PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for... PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The Company’s segments include Corporate and Research. The Company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The Company is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. It is focused on starting Phase II/III clinical study of MPL. It has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. It is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.More

Announcements


PAA MPL manufactured and tableting commencedPRICE SENSITIVE15/03/22 download Created with Sketch. 212.64KB
PAA Preliminary MPL antiviral leukaemia preclinical WEHI resultsPRICE SENSITIVE23/02/22 download Created with Sketch. 243.37KB
PAA Key Appointment to Progress MPL COVID-19 Clinical TrialPRICE SENSITIVE21/02/22 download Created with Sketch. 316.4KB
PAA Appendix 4D & Half Year ReportPRICE SENSITIVE18/02/22 download Created with Sketch. 1.08MB
PAA Epichem Confirms Effectiveness of OHD E-Waste ProjectPRICE SENSITIVE16/02/22 download Created with Sketch. 224KB
PAA Resignation of Epichem CEO03/02/22 download Created with Sketch. 187.14KB
PAA Update on Manufacture of MPL & Tablets for Clinical TrialsPRICE SENSITIVE02/02/22 download Created with Sketch. 202.99KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE31/01/22 download Created with Sketch. 848.78KB
PAA Epichem Awarded Contract Extension from DNDiPRICE SENSITIVE15/12/21 download Created with Sketch. 489.68KB
PAA Shareholder Update - Progress and StrategyPRICE SENSITIVE13/12/21 download Created with Sketch. 576.5KB
PAA Demonstration batch of smaller size MPL tablets completedPRICE SENSITIVE01/12/21 download Created with Sketch. 275.41KB
PAA MND & COVID-19 Phase 1 Clinical Trials On-TrackPRICE SENSITIVE17/11/21 download Created with Sketch. 218.35KB
PAA Cleansing Notice16/11/21 download Created with Sketch. 141.89KB
PAA Application for quotation of securities - PAA16/11/21 download Created with Sketch. 24.55KB
PAA Canine phase 2b cancer trial expands to New ZealandPRICE SENSITIVE15/11/21 download Created with Sketch. 234.84KB
PAA JobKeeper Payment Notification12/11/21 download Created with Sketch. 373.76KB
PAA Change of Director's Interest Notice x 409/11/21 download Created with Sketch. 250.43KB
PAA PAAO Top 20 Holders & Distribution Schedule09/11/21 download Created with Sketch. 35.01KB
PAA Application for quotation of securities - PAA09/11/21 download Created with Sketch. 24.81KB
PAA Closure of Entitlement Offer05/11/21 download Created with Sketch. 350.05KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE29/10/21 download Created with Sketch. 654.8KB
PAA Results of Annual General Meeting22/10/21 download Created with Sketch. 391.63KB
PAA AGM Presentation21/10/21 download Created with Sketch. 4.27MB
PAA MPL Manufacturing and Human Trials UpdatePRICE SENSITIVE21/10/21 download Created with Sketch. 223.25KB
PAA Following Extension of Survival, PAA Prepares Phase 3 TrialPRICE SENSITIVE18/10/21 download Created with Sketch. 247.8KB
PAA Proposed issue of securities - PAA01/10/21 download Created with Sketch. 30.27KB
PAA ProspectusPRICE SENSITIVE01/10/21 download Created with Sketch. 310.07KB
PAA Entitlement Options OfferPRICE SENSITIVE01/10/21 download Created with Sketch. 146.97KB
PAA Notice of Annual General Meeting/Proxy Form17/09/21 download Created with Sketch. 508.54KB
PAA Letter to shareholders re AGM17/09/21 download Created with Sketch. 76.44KB
PAA Broker Briefing Presentation Tech & Biotech Investor Webinar09/09/21 download Created with Sketch. 4.29MB
PAA Broker Briefing Investor Webinar07/09/21 download Created with Sketch. 184.35KB
PAA Epichem Completes Final Loan RepaymentPRICE SENSITIVE31/08/21 download Created with Sketch. 224.72KB
PAA Change of Director's Interest Notice24/08/21 download Created with Sketch. 181.96KB
PAA Application for quotation of securities - PAA24/08/21 download Created with Sketch. 27.06KB
PAA Appendix 4G & Corporate Governance Statement18/08/21 download Created with Sketch. 499.66KB
PAA Appendix 4E & Full Year Statutory AccountsPRICE SENSITIVE18/08/21 download Created with Sketch. 1.12MB
PAA Epichem Completes Build of OHD Benchtop Flow ReactorPRICE SENSITIVE03/08/21 download Created with Sketch. 211.58KB
PAA Virtual Investor Briefing30/07/21 download Created with Sketch. 366.64KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE28/07/21 download Created with Sketch. 522.09KB
PAA Monepantel and monepantel sulfone COVID-19 anti-viral updatePRICE SENSITIVE26/07/21 download Created with Sketch. 503.52KB
PAA PharmAust files patent for monepantel in viral diseases22/07/21 download Created with Sketch. 215.92KB
PAA PharmAust and WEHI to Investigate HTLV-1 Viral InfectionsPRICE SENSITIVE12/07/21 download Created with Sketch. 410.42KB
PAA Science Week Conference Presentation09/07/21 download Created with Sketch. 5.84MB
PAA PharmAust establishes monepantel GMP tablet stability07/07/21 download Created with Sketch. 388.35KB
PAA Phase IIb Dog Trial Achieves Interim Clinical EndpointsPRICE SENSITIVE28/06/21 download Created with Sketch. 447.83KB
PAA PharmAust receives ethics approval for Phase I trial in MNDPRICE SENSITIVE02/06/21 download Created with Sketch. 272.66KB
PAA Dr Kim Agnew appointed Principal Investigator of dog trial14/05/21 download Created with Sketch. 369.97KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE29/04/21 download Created with Sketch. 305.76KB
PAA Phase IIb Canine Trial Identifies Therapeutic Window for MPLPRICE SENSITIVE27/04/21 download Created with Sketch. 367.01KB
PAA Epichem OHD Presentation - Waste to Fuels Technology21/04/21 download Created with Sketch. 3.34MB
PAA PharmAust Receives $750k R&D Tax Incentive RefundPRICE SENSITIVE08/04/21 download Created with Sketch. 348.54KB
PAA Leiden Testing Indicates MPL SARS-CoV-2 Antiviral ActivityPRICE SENSITIVE07/04/21 download Created with Sketch. 531.65KB
PAA Trading HaltPRICE SENSITIVE06/04/21 download Created with Sketch. 412.74KB
PAA Pause in TradingPRICE SENSITIVE06/04/21 download Created with Sketch. 116.36KB
PAA Update on Phase IIb Clinical Trial of Monepantel in Pet DogsPRICE SENSITIVE30/03/21 download Created with Sketch. 392.54KB
PAA Epichem business support program for advanced technologies29/03/21 download Created with Sketch. 389.98KB
PAA Licensing Agreement to Develop Waste to Fuels TechnologyPRICE SENSITIVE23/03/21 download Created with Sketch. 324.8KB
PAA Appendix 4D & Half Year ReportPRICE SENSITIVE26/02/21 download Created with Sketch. 523.81KB
PAA Update on Phase IIb Clinical Trial recruitmentPRICE SENSITIVE15/02/21 download Created with Sketch. 346.6KB
PAA Update on COVID-19 testing in the Netherlands10/02/21 download Created with Sketch. 346.72KB
PAA Virtual Investor Briefing05/02/21 download Created with Sketch. 347.42KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE27/01/21 download Created with Sketch. 490.75KB
PAA Epichem Awarded $200K WasteSorted e-Waste GrantPRICE SENSITIVE22/01/21 download Created with Sketch. 389.54KB
PAA Leiden University Medical Centre Monepantel COVID-19 TestingPRICE SENSITIVE08/01/21 download Created with Sketch. 408.85KB
PAA PAA & ONJCRI to Continue MPL Pre-clinical InvestigationsPRICE SENSITIVE05/01/21 download Created with Sketch. 400.86KB
PAA Appendix 2A & s708 notice04/01/21 download Created with Sketch. 502.57KB
PAA PAA Commences Manufacture of GMP-Grade MPL for Human TrialsPRICE SENSITIVE23/12/20 download Created with Sketch. 388.13KB
PAA PharmAust to Commence Phase IIb Dog Cancer TrialPRICE SENSITIVE22/12/20 download Created with Sketch. 369.9KB
PAA Epichem Awarded Contract Extension from DNDiPRICE SENSITIVE21/12/20 download Created with Sketch. 402.45KB
PAA Appendix 2A & s708 notice (exercise of options)04/12/20 download Created with Sketch. 408.98KB
PAA Results of Annual General Meeting05/11/20 download Created with Sketch. 397.5KB
PAA AGM Shareholder Presentation05/11/20 download Created with Sketch. 1.77MB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE29/10/20 download Created with Sketch. 275.91KB
PAA Appendix 2A & s708 notice (exercise of employee options)21/10/20 download Created with Sketch. 409.11KB
PAA Appendix 3G21/10/20 download Created with Sketch. 280.13KB
PAA Appendix 2A & s708 notice12/10/20 download Created with Sketch. 419.04KB
PAA Notice of Annual General Meeting/Proxy Form02/10/20 download Created with Sketch. 497.83KB
PAA ONJCRI Evaluates Monepantel Anti-Cancer MechanismPRICE SENSITIVE29/09/20 download Created with Sketch. 390.86KB
PAA Clarification statement28/09/20 download Created with Sketch. 351.12KB
PAA PAA Evaluate MPL Suitability for Ex-Vivo Human COVID-19 TestPRICE SENSITIVE24/09/20 download Created with Sketch. 407.01KB
PAA PAA awarded grant for Phase I trial in Motor Neurone DiseasePRICE SENSITIVE21/09/20 download Created with Sketch. 406.07KB
PAA Appendix 4G & Corporate Governance Statement18/09/20 download Created with Sketch. 435.34KB
PAA Annual Report18/09/20 download Created with Sketch. 1.02MB
PAA PharmAust Shareholder UpdatePRICE SENSITIVE14/09/20 download Created with Sketch. 330.82KB
PAA Monepantel Anti-viral Activity Against SARS-CoV-2 ConfirmedPRICE SENSITIVE09/09/20 download Created with Sketch. 398.64KB
PAA Elanco Option UpdatePRICE SENSITIVE09/09/20 download Created with Sketch. 373.81KB
PAA Trading HaltPRICE SENSITIVE07/09/20 download Created with Sketch. 536.33KB
PAA Epichem in partnership to develop waste into fuel technologyPRICE SENSITIVE01/09/20 download Created with Sketch. 368.83KB
PAA Appendix 2A & s708 notice (exercise of employee options)31/08/20 download Created with Sketch. 409.45KB
PAA Appendix 4E & Preliminary Final ReportPRICE SENSITIVE31/08/20 download Created with Sketch. 313.61KB
PAA Inhibition of SARS-CoV-2 by MPL in Human Respiratory CellsPRICE SENSITIVE25/08/20 download Created with Sketch. 421.74KB
PAA Appendix 2A & s708 notice (exercise of staff options)07/08/20 download Created with Sketch. 410.27KB
PAA Appendix 2A & s708 notice (exercise of staff options)31/07/20 download Created with Sketch. 409.51KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE28/07/20 download Created with Sketch. 475.64KB
PAA Appendix 2A & s708 notice (exercise of options)24/07/20 download Created with Sketch. 411.07KB
PAA Appendix 2A & s708 notice (exercise of options)17/07/20 download Created with Sketch. 409.75KB
PAA Appendix 2A & s708 notice (exercise of options)15/07/20 download Created with Sketch. 409.47KB
PAA Final Report delivered under Option Agreement13/07/20 download Created with Sketch. 356.82KB
PAA Appendix 2A & s708 notice (exercise of options)10/07/20 download Created with Sketch. 452.83KB
PAA MPL manufactured and tableting commenced
15/03/22PRICE SENSITIVE download Created with Sketch. 212.64KB
PAA Preliminary MPL antiviral leukaemia preclinical WEHI results
23/02/22PRICE SENSITIVE download Created with Sketch. 243.37KB
PAA Key Appointment to Progress MPL COVID-19 Clinical Trial
21/02/22PRICE SENSITIVE download Created with Sketch. 316.4KB
PAA Appendix 4D & Half Year Report
18/02/22PRICE SENSITIVE download Created with Sketch. 1.08MB
PAA Epichem Confirms Effectiveness of OHD E-Waste Project
16/02/22PRICE SENSITIVE download Created with Sketch. 224KB
PAA Resignation of Epichem CEO
03/02/22 download Created with Sketch. 187.14KB
PAA Update on Manufacture of MPL & Tablets for Clinical Trials
02/02/22PRICE SENSITIVE download Created with Sketch. 202.99KB
PAA Appendix 4C and Quarterly Update
31/01/22PRICE SENSITIVE download Created with Sketch. 848.78KB
PAA Epichem Awarded Contract Extension from DNDi
15/12/21PRICE SENSITIVE download Created with Sketch. 489.68KB
PAA Shareholder Update - Progress and Strategy
13/12/21PRICE SENSITIVE download Created with Sketch. 576.5KB
PAA Demonstration batch of smaller size MPL tablets completed
01/12/21PRICE SENSITIVE download Created with Sketch. 275.41KB
PAA MND & COVID-19 Phase 1 Clinical Trials On-Track
17/11/21PRICE SENSITIVE download Created with Sketch. 218.35KB
PAA Cleansing Notice
16/11/21 download Created with Sketch. 141.89KB
PAA Application for quotation of securities - PAA
16/11/21 download Created with Sketch. 24.55KB
PAA Canine phase 2b cancer trial expands to New Zealand
15/11/21PRICE SENSITIVE download Created with Sketch. 234.84KB
PAA JobKeeper Payment Notification
12/11/21 download Created with Sketch. 373.76KB
PAA Change of Director's Interest Notice x 4
09/11/21 download Created with Sketch. 250.43KB
PAA PAAO Top 20 Holders & Distribution Schedule
09/11/21 download Created with Sketch. 35.01KB
PAA Application for quotation of securities - PAA
09/11/21 download Created with Sketch. 24.81KB
PAA Closure of Entitlement Offer
05/11/21 download Created with Sketch. 350.05KB
PAA Appendix 4C and Quarterly Update
29/10/21PRICE SENSITIVE download Created with Sketch. 654.8KB
PAA Results of Annual General Meeting
22/10/21 download Created with Sketch. 391.63KB
PAA AGM Presentation
21/10/21 download Created with Sketch. 4.27MB
PAA MPL Manufacturing and Human Trials Update
21/10/21PRICE SENSITIVE download Created with Sketch. 223.25KB
PAA Following Extension of Survival, PAA Prepares Phase 3 Trial
18/10/21PRICE SENSITIVE download Created with Sketch. 247.8KB
PAA Proposed issue of securities - PAA
01/10/21 download Created with Sketch. 30.27KB
PAA Prospectus
01/10/21PRICE SENSITIVE download Created with Sketch. 310.07KB
PAA Entitlement Options Offer
01/10/21PRICE SENSITIVE download Created with Sketch. 146.97KB
PAA Notice of Annual General Meeting/Proxy Form
17/09/21 download Created with Sketch. 508.54KB
PAA Letter to shareholders re AGM
17/09/21 download Created with Sketch. 76.44KB
PAA Broker Briefing Presentation Tech & Biotech Investor Webinar
09/09/21 download Created with Sketch. 4.29MB
PAA Broker Briefing Investor Webinar
07/09/21 download Created with Sketch. 184.35KB
PAA Epichem Completes Final Loan Repayment
31/08/21PRICE SENSITIVE download Created with Sketch. 224.72KB
PAA Change of Director's Interest Notice
24/08/21 download Created with Sketch. 181.96KB
PAA Application for quotation of securities - PAA
24/08/21 download Created with Sketch. 27.06KB
PAA Appendix 4G & Corporate Governance Statement
18/08/21 download Created with Sketch. 499.66KB
PAA Appendix 4E & Full Year Statutory Accounts
18/08/21PRICE SENSITIVE download Created with Sketch. 1.12MB
PAA Epichem Completes Build of OHD Benchtop Flow Reactor
03/08/21PRICE SENSITIVE download Created with Sketch. 211.58KB
PAA Virtual Investor Briefing
30/07/21 download Created with Sketch. 366.64KB
PAA Appendix 4C and Quarterly Update
28/07/21PRICE SENSITIVE download Created with Sketch. 522.09KB
PAA Monepantel and monepantel sulfone COVID-19 anti-viral update
26/07/21PRICE SENSITIVE download Created with Sketch. 503.52KB
PAA PharmAust files patent for monepantel in viral diseases
22/07/21 download Created with Sketch. 215.92KB
PAA PharmAust and WEHI to Investigate HTLV-1 Viral Infections
12/07/21PRICE SENSITIVE download Created with Sketch. 410.42KB
PAA Science Week Conference Presentation
09/07/21 download Created with Sketch. 5.84MB
PAA PharmAust establishes monepantel GMP tablet stability
07/07/21 download Created with Sketch. 388.35KB
PAA Phase IIb Dog Trial Achieves Interim Clinical Endpoints
28/06/21PRICE SENSITIVE download Created with Sketch. 447.83KB
PAA PharmAust receives ethics approval for Phase I trial in MND
02/06/21PRICE SENSITIVE download Created with Sketch. 272.66KB
PAA Dr Kim Agnew appointed Principal Investigator of dog trial
14/05/21 download Created with Sketch. 369.97KB
PAA Appendix 4C and Quarterly Update
29/04/21PRICE SENSITIVE download Created with Sketch. 305.76KB
PAA Phase IIb Canine Trial Identifies Therapeutic Window for MPL
27/04/21PRICE SENSITIVE download Created with Sketch. 367.01KB
PAA Epichem OHD Presentation - Waste to Fuels Technology
21/04/21 download Created with Sketch. 3.34MB
PAA PharmAust Receives $750k R&D Tax Incentive Refund
08/04/21PRICE SENSITIVE download Created with Sketch. 348.54KB
PAA Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity
07/04/21PRICE SENSITIVE download Created with Sketch. 531.65KB
PAA Trading Halt
06/04/21PRICE SENSITIVE download Created with Sketch. 412.74KB
PAA Pause in Trading
06/04/21PRICE SENSITIVE download Created with Sketch. 116.36KB
PAA Update on Phase IIb Clinical Trial of Monepantel in Pet Dogs
30/03/21PRICE SENSITIVE download Created with Sketch. 392.54KB
PAA Epichem business support program for advanced technologies
29/03/21 download Created with Sketch. 389.98KB
PAA Licensing Agreement to Develop Waste to Fuels Technology
23/03/21PRICE SENSITIVE download Created with Sketch. 324.8KB
PAA Appendix 4D & Half Year Report
26/02/21PRICE SENSITIVE download Created with Sketch. 523.81KB
PAA Update on Phase IIb Clinical Trial recruitment
15/02/21PRICE SENSITIVE download Created with Sketch. 346.6KB
PAA Update on COVID-19 testing in the Netherlands
10/02/21 download Created with Sketch. 346.72KB
PAA Virtual Investor Briefing
05/02/21 download Created with Sketch. 347.42KB
PAA Appendix 4C and Quarterly Update
27/01/21PRICE SENSITIVE download Created with Sketch. 490.75KB
PAA Epichem Awarded $200K WasteSorted e-Waste Grant
22/01/21PRICE SENSITIVE download Created with Sketch. 389.54KB
PAA Leiden University Medical Centre Monepantel COVID-19 Testing
08/01/21PRICE SENSITIVE download Created with Sketch. 408.85KB
PAA PAA & ONJCRI to Continue MPL Pre-clinical Investigations
05/01/21PRICE SENSITIVE download Created with Sketch. 400.86KB
PAA Appendix 2A & s708 notice
04/01/21 download Created with Sketch. 502.57KB
PAA PAA Commences Manufacture of GMP-Grade MPL for Human Trials
23/12/20PRICE SENSITIVE download Created with Sketch. 388.13KB
PAA PharmAust to Commence Phase IIb Dog Cancer Trial
22/12/20PRICE SENSITIVE download Created with Sketch. 369.9KB
PAA Epichem Awarded Contract Extension from DNDi
21/12/20PRICE SENSITIVE download Created with Sketch. 402.45KB
PAA Appendix 2A & s708 notice (exercise of options)
04/12/20 download Created with Sketch. 408.98KB
PAA Results of Annual General Meeting
05/11/20 download Created with Sketch. 397.5KB
PAA AGM Shareholder Presentation
05/11/20 download Created with Sketch. 1.77MB
PAA Appendix 4C and Quarterly Update
29/10/20PRICE SENSITIVE download Created with Sketch. 275.91KB
PAA Appendix 2A & s708 notice (exercise of employee options)
21/10/20 download Created with Sketch. 409.11KB
PAA Appendix 3G
21/10/20 download Created with Sketch. 280.13KB
PAA Appendix 2A & s708 notice
12/10/20 download Created with Sketch. 419.04KB
PAA Notice of Annual General Meeting/Proxy Form
02/10/20 download Created with Sketch. 497.83KB
PAA ONJCRI Evaluates Monepantel Anti-Cancer Mechanism
29/09/20PRICE SENSITIVE download Created with Sketch. 390.86KB
PAA Clarification statement
28/09/20 download Created with Sketch. 351.12KB
PAA PAA Evaluate MPL Suitability for Ex-Vivo Human COVID-19 Test
24/09/20PRICE SENSITIVE download Created with Sketch. 407.01KB
PAA PAA awarded grant for Phase I trial in Motor Neurone Disease
21/09/20PRICE SENSITIVE download Created with Sketch. 406.07KB
PAA Appendix 4G & Corporate Governance Statement
18/09/20 download Created with Sketch. 435.34KB
PAA Annual Report
18/09/20 download Created with Sketch. 1.02MB
PAA PharmAust Shareholder Update
14/09/20PRICE SENSITIVE download Created with Sketch. 330.82KB
PAA Monepantel Anti-viral Activity Against SARS-CoV-2 Confirmed
09/09/20PRICE SENSITIVE download Created with Sketch. 398.64KB
PAA Elanco Option Update
09/09/20PRICE SENSITIVE download Created with Sketch. 373.81KB
PAA Trading Halt
07/09/20PRICE SENSITIVE download Created with Sketch. 536.33KB
PAA Epichem in partnership to develop waste into fuel technology
01/09/20PRICE SENSITIVE download Created with Sketch. 368.83KB
PAA Appendix 2A & s708 notice (exercise of employee options)
31/08/20 download Created with Sketch. 409.45KB
PAA Appendix 4E & Preliminary Final Report
31/08/20PRICE SENSITIVE download Created with Sketch. 313.61KB
PAA Inhibition of SARS-CoV-2 by MPL in Human Respiratory Cells
25/08/20PRICE SENSITIVE download Created with Sketch. 421.74KB
PAA Appendix 2A & s708 notice (exercise of staff options)
07/08/20 download Created with Sketch. 410.27KB
PAA Appendix 2A & s708 notice (exercise of staff options)
31/07/20 download Created with Sketch. 409.51KB
PAA Appendix 4C and Quarterly Update
28/07/20PRICE SENSITIVE download Created with Sketch. 475.64KB
PAA Appendix 2A & s708 notice (exercise of options)
24/07/20 download Created with Sketch. 411.07KB
PAA Appendix 2A & s708 notice (exercise of options)
17/07/20 download Created with Sketch. 409.75KB
PAA Appendix 2A & s708 notice (exercise of options)
15/07/20 download Created with Sketch. 409.47KB
PAA Final Report delivered under Option Agreement
13/07/20 download Created with Sketch. 356.82KB
PAA Appendix 2A & s708 notice (exercise of options)
10/07/20 download Created with Sketch. 452.83KB
(20min delay)
Last
17.0¢
Change
-0.010(5.56%)
Mkt cap ! $67.30M
Open High Low Value Volume
17.5¢ 18.0¢ 16.3¢ $581.7K 3.408M

Buyers (Bids)

No. Vol. Price($)
4 502428 17.0¢
 

Sellers (Offers)

Price($) Vol. No.
17.5¢ 40529 1
View Market Depth
Last trade - 16.10pm 10/05/2024 (20 minute delay) ?
Last
17.5¢
  Change
-0.010 ( 3.15 %)
Open High Low Volume
17.5¢ 18.0¢ 16.0¢ 3492891
Last updated 15.59pm 10/05/2024 ?
PAA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.